Quoin Pharmaceuticals Ltd. 2025 Annual Report: Key Investor Highlights

Company Overview

Quoin Pharmaceuticals Ltd. (“Quoin” or “the Company”) is an Israeli pharmaceutical company whose American Depositary Shares (ADSs), each representing thirty-five ordinary shares, are listed on Nasdaq under the trading symbol QNRX. The company underwent a significant ADS ratio change effective April 9, 2025, shifting from 1 ADS representing one ordinary share to 1 ADS representing thirty-five ordinary shares, resulting in a 1-for-35 reverse split of issued and outstanding ADSs. Ordinary shares themselves were unaffected, but all related financial and share information has been retroactively adjusted to reflect this change.

Financial Position and Capital Requirements

• Limited Operating History and Losses: The Company has a limited operating history and has incurred significant losses since inception. It has never generated revenue from product sales or any other sources.
• Need for Additional Capital: Quoin must raise additional capital to fund its operations and continue as a going concern. Current cash resources are limited, and future capital raises may not be on acceptable terms, or achievable at all.
• October 2025 Private Placement: The terms of this private placement may complicate efforts to procure additional financing, potentially impacting liquidity and the ability to execute business plans.
• Public Float: As of June 30, 2025, Quoin’s aggregate market value of voting equity held by non-affiliates was approximately \$5.4 million, with no non-voting equity outstanding.

Regulatory and Listing Status

• Quoin is an accelerated filer and a smaller reporting company, but not an emerging growth company.
• The company has complied with all SEC reporting requirements and submitted all required Interactive Data Files, remaining in good standing.
• Nasdaq Listing Risk: The company faces risks related to maintaining compliance with Nasdaq’s continued listing requirements. Failure to comply could result in delisting, which would significantly impact liquidity and shareholder value.

Key Risks and Forward-Looking Statements

• Going Concern Risk: Management has highlighted the need to raise additional capital to continue operations. If unsuccessful, Quoin may not be able to continue as a going concern.
• Regulatory Approval Uncertainty: Even if product candidates are approved, extensive regulatory requirements and development challenges remain.
• Potential Dilution: Future issuances of equity may substantially dilute existing shareholders’ ownership.
• Market Volatility: The price of ADSs may be highly volatile. Adverse analyst coverage, substantial future sales, or perceived potential sales of ADSs could negatively impact share price.
• Control via ADS Depositary: Holders of ADSs must act through the depositary to exercise shareholder rights and may face limitations on the transfer of ADSs.
• Business and Development Risks: The Company faces uncertainties regarding cash flow, working capital needs, the success of clinical trials, and the competitive landscape.
• Legal and Regulatory Risks: Shareholders may face difficulties enforcing U.S. judgments in Israel, and Israeli law governs shareholder rights, which may differ from U.S. standards.

Potential Price-Sensitive Developments

• Reverse Split and Ratio Change: The adjustment in the ADS ratio and reverse split can impact share price through changes in liquidity and perception.
• Requirement for Additional Capital: The explicit statement that Quoin needs to raise more funds and may not be able to do so is highly price-sensitive.
• Nasdaq Listing Risk: If Quoin fails to maintain its Nasdaq listing, shareholder value and liquidity will be significantly affected.
• Pivotal Clinical Development: The company has received feedback from the FDA regarding Phase 3 study design, expressing openness to alternative designs. This may influence future regulatory timelines and market prospects.

Summary of Risk Factors

• Financial Risks: Lack of revenue, historical losses, need for capital, and potential inability to procure funding.
• Development Risks: Failure to capitalize on profitable product candidates, competition, potential lack of reimbursement, and regulatory hurdles.
• Operational Risks: Reliance on third parties, risk of employee misconduct, business interruptions, and exposure to litigation.
• Ownership Risks: Market volatility, risk of dilution, dependence on depositary, transfer limitations, and risks related to being an Israeli company.

Conclusion

Quoin Pharmaceuticals Ltd. is in a critical phase, facing significant financial, regulatory, and operational challenges. The need for additional capital, changes in ADS structure, and risks relating to Nasdaq listing compliance are all highly price-sensitive and may affect shareholder value. Investors should carefully weigh these factors before making investment decisions, as the company’s future prospects depend on their ability to raise funds, advance product development, and maintain regulatory compliance.

Disclaimer: This article is based on the Quoin Pharmaceuticals Ltd. Annual Report for year ended December 31, 2025, and is intended for informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with a professional advisor before making any investment decisions. The company may make further disclosures or updates, and past performance is not indicative of future results.

View Quoin Pharmaceuticals, Ltd. Historical chart here